RxSight, Inc.

RXST Healthcare Medical Devices

RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024.

Revenue
−19.0%
EPS
−62.1%
Free cash flow
+2,591.1%

Quarter to September 2026, against a year earlier

4.57 0.03 +0.66%
Market cap
$190.4M
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
5.03
Beneish M
−3.15
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
1.68 1.57 2.00 3.17
P/FCF ratio
10.96 0.00 0.00 0.00
P/Operating CF
4.52 (20.97) (23.36) (381.42)
P/B ratio
0.80 0.76 0.95 1.54
EV/Sales
(0.25) 0.08 0.44 1.61
EV/EBITDA
0.47 0.00 0.00 0.00
EV/FCF
(1.65) (0.40) (2.60) (11.23)
Current Ratio
4.20 4.07 10.20 10.95
Net Debt/EBITDA
13.20 14.38 11.56 18.52
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(26.10%) (23.44%) (18.34%) (9.12%)
Free Cash Flow Yield
9.12% (13.58%) (8.48%) (4.54%)
Free Cash Flow per Share
1.06 (0.28) (0.28) (0.06)
Book value per Share
6.11 6.35 6.47 6.75
Free Cash Flow
44.04 (11.49) (11.65) (2.25)
EV/EBIT
0.50 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026